FDA approval: Ryoncil (from Catapult’s regulatory round-up for December 2024)
FDA has approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Steroid-refractory acute graft-versus-host disease is a serious and life-threatening condition that can occur as a complication of allogeneic hematopoietic (blood) stem cell transplantation (allo-HSCT). MSCs are a type of cell that can have various roles in the body and can differentiate into multiple other types of cells. These MSCs are isolated from the bone marrow of healthy adult human donors. Ryoncil is the first MSC therapy to treat steroid-refractory acute graft-versus-host disease. Please find further information here.
Published on the 9th of January 2025. Read the entire Regulatory Round-up – December 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (12 février 2025). FDA approval: Ryoncil (from Catapult’s regulatory round-up for December 2024). ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/13axz





